Adverse cutaneous reactions of COVID-19 treatment

author

  • , Department of Dermatology, Sina Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract:

COVID-19 pandemic has led to many mortalities since the beginning of 2020. As there was no previous experience, no specific therapy was used, except for gloves, masks, special clothes, and antiseptics. So various pharmacologic and non-pharmacological treatments were tried. World Health Organization published therapeutic protocols in the first weeks of the pandemic that has been changed over months. As there are constant and variable signs and symptoms in different patients in different countries, therapeutic modalities and drugs are various too. Some of these drugs have been used for viral and nonviral diseases, including Tamiflu (that has been used in the treatment of influenza), Ribavirin (an effective drug in hepatitis C infection), immunoglobulin (that has been used in the treatment of various disorders like Stevens-Johnson syndrome), hydroxychloroquine (for the treatment of systemic lupus erythematosus and other rheumatologic disorders), azithromycin (that is used for upper respiratory tract infections, acne, etc.). On the other hand, consuming spices such as ginger and turmeric, vitamins like vitamin C and vitamin D, and zinc supplements have been suggested. Over months, treatment complications, including side effects of drugs and protective equipment appeared. Complications included a broad spectrum of pruritus and nonspecific rash to Stevens-Johnson syndrome and angioedema. Aggravation and recurrence of dermatitis due to the use of protective equipment and antiseptics have been observed. Increasing knowledge about treatment complications will result in early diagnosis and management and obviously decreasing mortality rates and costs. This article is a review of common cutaneous side effects of therapeutic modalities and preventive methods in COVID-19.  

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Severe Cutaneous Adverse Reactions

Severe cutaneous adverse reactions (SCARs) are generally induced by drugs and encompass the conditions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug induced eosinophilia and systemic syndrome (DRESS) also known as drug induced hypersensitivity syndrome (DIHS), and acute generalized exanthematous pustulosis (AGEP). These conditions, although rare, cause significant...

full text

Adverse cutaneous drug reactions

| August 2014 | 798 Finally, the authors detected a higher prevalence of more serious and life-threatening types of ACDR like Stevens Johnson and toxic epidermal necrolysis in their study. This finding is so important and may be due to the difference in type and potency of metabolic pathways in Iranian patients due to their ethnic groups, or it may be due to not including the above mentioned ri...

full text

Cutaneous Adverse Reactions of Amiodarone

Dermatological complications of amiodarone are commonly encountered problems in therapy. The incidence in the population of patients with prolonged use of amiodarone reaches nearly 75% according to various sources. Nevertheless, they are often misdiagnosed or overlooked. The aim of this review is to present the current state of knowledge about skin changes induced by amiodarone, including photo...

full text

Cutaneous adverse drug reactions: A one year prospective study

Background: Adverse cutaneous drug reactions are unwarranted effects of modern medicine. These unfortunate events can assume any morphology from simple exanthem to full blown toxic epidermal necrolysis (TEN), and can simulate and mimic many diseases. Sometimes it is difficult to recognize the cause, but they may be due to polypharmacy or self-administration of medications. The analytical data f...

full text

[Adverse cutaneous reactions to erlotinib].

INTRODUCTION Erlotinib is an inhibitor of human epidermal growth factor approved for treating non-small cell lung cancer. The aim of this prospective observational study was to determine the prevalence of adverse cutaneous reactions caused by erlotinib and assess the management of such effects. METHODS Eleven patients with lung cancer and 1 with ovarian cancer received erlotinib at a dose of ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 13  issue 1

pages  53- 62

publication date 2022-05

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023